ATROVENT NASAL SUMMARY
The active ingredient in ATROVENT® Nasal Spray is ipratropium bromide monohydrate.
ATROVENT® (ipratropium bromide) Nasal Spray 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. ATROVENT (ipratropium bromide) Nasal Spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis.
|
NEWS HIGHLIGHTS
Published Studies Related to Atrovent Nasal (Ipratropium Nasal)
Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia. [2008.03]
Idiopathic rhinitis without eosinophilia is a group of frequently observed diseases, the aetiopathogenesis of which is not yet well known. One of the most disturbing symptoms for patients within this disease group is nasal hypersecretion.As a result, while IB and BTX-A differ in terms of method of application, they display a similar degree and duration of efficiency in hypersecretion therapy.
The effect of ipratropium nasal spray on bronchial methacholine challenge. [2005.09]
PURPOSES: To determine the effect ipratropium bromide nasal spray has on methacholine challenge testing for airway hyperresponsiveness... CONCLUSIONS: Pretreatment with nasal ipratropium results in a small increase in PC20. Although this difference achieves statistical significance, it is probably not clinically significant.
Cold-induced rhinitis in skiers--clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial. [2001.09]
Cold-induced rhinitis (CIR) is common among skiers and is perceived as a troublesome disease. We studied the clinical characteristics of CIR in a population of skiers and we evaluated the effectiveness of ipratropium bromide nasal spray (IBNS) in relieving symptoms in a double-blind placebo-controlled fashion...
Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient: a pilot study. [2001.05]
Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control. This study was undertaken to evaluate the effect of ipratropium bromide (IB), an anticholinergic nasal spray, on rhinorrhea in these patients... We suggest ipratropium nasal spray as a safe, effective way to treat chronic rhinorrhea in laryngectomized patients, improving their quality of life.
Ipratropium bromide increases the ability of the nose to warm and humidify air. [2000.09]
We have developed a method for measuring the temperature and relative humidity of air prior to and after nasal conditioning and used it to study the effect of treatment with ipratropium bromide on the ability of the nose to condition cold, dry air. We performed randomized, double-blind, placebo-controlled, two-way crossover studies and an open study in nonallergic subjects...
Clinical Trials Related to Atrovent Nasal (Ipratropium Nasal)
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT� Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Completed]
The objective of this study was to determine the pharmacokinetic comparability of 84 µg
ipratropium bromide HFA-134a inhalation aerosol and 84 µg ATROVENT® CFC Inhalation Aerosol
in COPD patients
Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes [Completed]
This will be a double-blind placebo-controlled study in which we plan to study 40
competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen
uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests
the athletes will randomly receive inhaled placebo or inhaled ipratropium bromide. We will
compare the athletes' airway response to the exercise challenge with and without the active
drug.
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Completed]
To compare the bronchodilator efficacy and safety of tiotropium inhalation capsules (18 µg
once daily) and Atrovent® MDI (2 puffs of 20µg q. i.d.) among Filipino patients with COPD
Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients [Completed]
The objectives of this study are to assess the effect of salbutamol in comparison with
ipratropium bromide on the geometry of central and peripheral airways and to correlate
spirometric indices with the Computational Fluid Dynamics (CFD) based calculated airway
volumes and resistances for both compounds.
Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease [Completed]
The objective of this study is to confirm that chronic dosing of 20 mcg and 40 mcg of
ipratropium bromide, administered via the RESPIMAT device, demonstrates clinical
comparability and similar safety profiles to the 36 mcg dose of ATROVENT® Inhalation Aerosol
(containing chlorinated fluorocarbons (CFC)) in patients with chronic obstructive pulmonary
disease (COPD). The efficacy and safety profiles of the two doses administered via the
RESPIMAT device will also be compared to their respective placebo groups
|
